This combination ophthalmic solution is used to lower elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

This ophthalmic formulation contains two active ingredients: Brimonidine Tartrate and Timolol Maleate. Brimonidine Tartrate is a selective alpha-2 adrenergic receptor agonist that works through a dual mechanism by reducing aqueous humor production and enhancing uveoscleral outflow. Timolol Maleate is a beta-adrenergic receptor blocker that lacks significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) effects. It lowers intraocular pressure by decreasing aqueous humor production. The combination of these two agents provides a rapid onset of action, with maximum intraocular pressure reduction typically achieved within two hours of administration.

Instill 1 drop in the affected eye(s) twice daily.

No specific drug interaction studies have been carried out for this combination.

This medication is contraindicated in patients with hypersensitivity to any of its components. It is also contraindicated in patients with bronchial asthma, severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock.

The most frequently reported side effects include allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, itching of the eyes, and burning or stinging sensation in the eyes.

There are no adequate and well-controlled studies in pregnant women. This combination should be used during pregnancy only if the expected benefit outweighs the potential risk to the fetus. Timolol has been detected in human breast milk, while it is not known whether Brimonidine is excreted in human milk. A decision should be made whether to discontinue breastfeeding or discontinue the medication, considering the importance of therapy to the mother.

Like other ophthalmic medications, this drug may be systemically absorbed. Due to the presence of Timolol, cardiovascular and pulmonary adverse effects similar to those seen with systemic beta-blockers may occur. Caution is advised in patients with severe, unstable, or uncontrolled cardiovascular or pulmonary diseases.

Use in children: Safety and effectiveness in children below 2 years of age have not been established.

Use in elderly patients: No significant differences in safety or effectiveness have been observed between elderly and adult patients.

Drugs for miotics and glaucoma

Store in a cool and dry place, protected from light. Do not use the product for more than 30 days after first opening. Keep out of reach of children.